<DOC>
	<DOCNO>NCT00718965</DOCNO>
	<brief_summary>The present study aim assess efficacy safety AVE5530 ( 25mg 50mg ) double-blind comparison placebo management patient primary hypercholesterolemia . The main objective evaluate effect AVE5530 LDL-C level reduction adjunct control diet . The effect AVE5530 lipid parameter assess secondary objective .</brief_summary>
	<brief_title>Evaluation Efficacy Safety AVE5530 Patients With Primary Hypercholesterolemia</brief_title>
	<detailed_description>The study include 2-week pre-randomization placebo lead-in phase double-blind treatment period least 12 month variably extend approximately 18 month .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Adults high cholesterol level either receive willing able discontinue ongoing lipidlowering therapy LDLC level &gt; 250 mg/dL ( 6.48 mmol/L ) Triglycerides level &gt; 350mg/dL ( 3.95 mmol/L ) Conditions / situation : presence clinically significant uncontrolled endocrine disease know influence lipid level Active liver disease High estimate risk Coronary Heart Disease Recent history congestive heart failure , unstable angina pectoris , myocardial infarction , coronary bypass surgery angioplasty , Unstable severe peripheral artery disease Positive test Hepatitis B surface antigen and/or Hepatitis C antibody Known Human Immunodeficient Virus ( HIV ) positive Pregnant breastfeeding woman , Women childbearing potential protected effective contraceptive method birth control ( include oral contraceptive ) and/or unwilling unable test pregnancy prior exposure Investigational Product . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Primary hypercholesterolemia</keyword>
</DOC>